WebDec 2, 2024 · Meredith M. Regan, ScD, Harvard Medical School, Boston, MA, gives an update on the 12-year follow-up results of the SOFT (NCT00066690) and TEXT (NCT00066703) … WebJul 8, 2024 · 5. 2024 Update of SOFT & TEXT trial • adding ovarian function suppression to tamoxifen significantly decreased the relative risk of disease-free survival events by 24% …
Designs for the TEXT (IBCSG 25-02/BIG 3-02) and SOFT
WebDec 7, 2024 · The two international trials, dubbed SOFT and TEXT, are evaluating post-surgical hormone-blocking therapy in more than 5,700 premenopausal women with early … WebJul 1, 2016 · Purpose: Risk of recurrence is the primary consideration in breast cancer adjuvant therapy recommendations. The TEXT (Tamoxifen and Exemestane Trial) and SOFT (Suppression of Ovarian Function Trial) trials investigated adjuvant endocrine therapies for premenopausal women with hormone receptor-positive breast cancer, testing … sideways cbbc
Simplified Explanation of the SOFT and TEXT Research
WebSOFT and TEXT are phase III clinical trials developed in parallel to test the optimal post-operative (i.e. adjuvant) endocrine treatment in premenopausal women with hormone … WebApr 17, 2024 · The benefits of ovarian suppression in premenopausal women with breast cancer were evaluated by the International Breast Cancer Study Group in the Tamoxifen and EXemestane Trial (TEXT) and the Suppression of Ovarian Function Trial (SOFT). 21 From these studies, further analysis was performed to determine the benefit of ovarian … Webin the SOFT trial, 12.3% (n ¼ 525) in the TEAM trial, 12.3% (n ¼ 329) in the TEXT trial and 100% in the ALTTO trial. Four trials included postmenopausal patients, while the TEXT and SOFT trials16 included only premenopausal patients. In the present meta-analysis, we included only ESMO Open S. Peleg Hasson et al. the plural of rhonchus is